Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00435292 · ClinicalTrials.gov registry record · NA

Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

A NA study of Osteoarthritis, sponsored by Primus Pharmaceuticals.

Completed
Registry status
NA
Development phase
350
Enrollment target
1
Study location

NCT00435292 is a NA study of Osteoarthritis that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 350 participants, below the 815-participant average among 135 other Osteoarthritis trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00435292, a NA study of Osteoarthritis, has completed, sponsored by Primus Pharmaceuticals.

COMPLETED
Registry status
NA
Development phase
350 participants
Enrollment target
1
Study location

Study Summary

Randomized, double-blind, placebo controlled parallel group, multi center study in subjects with moderate-severe osteoarthritis.

Conditions Studied

Osteoarthritis

Interventions

  • DRUG Naproxen
  • DIETARY_SUPPLEMENT flavocoxid 250 mg
  • DIETARY_SUPPLEMENT flavocoxid 500 mg

Study Locations (1)

Arizona

  • Primus Pharmaceuticals, Inc - Scottsdale

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2006-04
Est. Completion 2007-12
Phase NA

Sponsor

Primus Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00435292

The ClinicalTrials.gov registry entry for NCT00435292 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 815-participant average among 135 other Osteoarthritis trials with a reported enrollment target (57% lower). The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 3 interventions - of which Naproxen is the first listed.

NCT00435292 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT00435292 about?

NCT00435292 is a clinical study titled "Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee". Randomized, double-blind, placebo controlled parallel group, multi center study in subjects with moderate-severe osteoarthritis.

What is the current status of trial NCT00435292?

This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2006-04. Estimated completion is 2007-12.

What conditions does trial NCT00435292 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT00435292?

The interventions under investigation include: Naproxen (DRUG), flavocoxid 250 mg (DIETARY_SUPPLEMENT), flavocoxid 500 mg (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00435292?

This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00435292 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoarthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.